Expression of endogenous galectin-1 and galectin-3 in intrahepatic cholangiocarcinoma.
Galectins, a family of beta-galactoside-binding animal lectins, might be involved in tumor progression. In this study, the expression patterns of galectin-1 and -3 were examined immunohistochemically in intrahepatic cholangiocarcinoma (ICC), with emphasis on its development and progression as well as its histopathologic features, by use of samples of normal intrahepatic bile duct (n = 20), biliary epithelial dysplasia (n = 15), ICC (n = 40), and a cholangiocarcinoma cell line, CCKS1. In normal intrahepatic bile ducts, galectin-3 was constitutively but weakly expressed, whereas galectin-1 was not expressed. In hepatolithiasis, biliary epithelial dysplasia was strongly positive for galectin-3 but negative for galectin-1. Galectin-3 was frequently and strongly expressed in the cytoplasm of well-differentiated ICCs, and its expression was significantly decreased and less intense or even absent in poorly differentiated ICCs. Galectin-1 was expressed in carcinoma cells in ICC, and its incidence and extent were correlated with histologic dedifferentiation of ICC. Proliferative cell nuclear antigen (PCNA) labeling index (LI) was higher in ICC cases positive for galectin-1 than in those that were negative. Galectin-1 was strongly expressed in cancerous stroma of ICC, and this stromal expression was related to histologic dedifferentiation of ICC. In the carcinoma cell line CCKS1, galectin-1 and -3 were expressed in the cytoplasm of carcinoma cells, and galectin-1 was additionally detected in the culture medium. These results suggest that galectin-1 was newly expressed on carcinoma cells of ICC, and its overexpression seems to be associated with neoplastic progression and proliferative activities, and the expression of galectin-1 in cancerous stroma may also be related to the progression of ICC. Galectin-3 expression in epithelial cells is up-regulated in the preneoplastic and early neoplastic stages of ICC, although galectin-3 tends to disappear at later stages of ICC. HUM PATHOL 32:302-310.
Shimonishi
T
T
Department of Pathology II, Kanazawa University School of Medicine, Kanazawa, Japan.
Miyazaki
K
K
Kono
N
N
Sabit
H
H
Tuneyama
K
K
Harada
K
K
Hirabayashi
J
J
Kasai
K
K
Nakanuma
Y
Y
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000943:Antigens, Differentiation / Q000032:analysis*; D001650:Bile Duct Neoplasms / Q000737:chemistry*; D001653:Bile Ducts, Intrahepatic / Q000737:chemistry*; D001659:Biliary Tract / Q000473:pathology; D002462:Cell Membrane / Q000737:chemistry; D018281:Cholangiocarcinoma / Q000737:chemistry*; D003593:Cytoplasm / Q000737:chemistry; D004847:Epithelial Cells / Q000473:pathology; D005260:Female; D037483:Galectin 1; D037502:Galectin 3; D006388:Hemagglutinins / Q000032:analysis*; D022781:Hepatocytes / Q000737:chemistry; D006801:Humans; D006965:Hyperplasia; D015151:Immunoblotting; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis; D014407:Tumor Cells, Cultured
D000943:Antigens, Differentiation; D037483:Galectin 1; D037502:Galectin 3; D006388:Hemagglutinins; D018809:Proliferating Cell Nuclear Antigen